Skip to main content

Table 1 Comparison of the baseline characteristics of the patients in the PCD and POBA groups and the 1, 2 and 5 years mortality rates

From: Paclitaxel and mortality in patients with claudication and de novo femoropopliteal lesions: a historical cohort study

  POBA (n = 380) PCD (n = 320) p-value
Age 67.7y + −8.8 68.5y + − 8.2 p = 0.14
Female 27.1% (n = 103) 27.8% (n = 89) p = 0.835
Active Tobacco Use 23.4% n = (89) 14.7% (n = 47) p = 0.004
Cancer 10.5% n = (40) 10.3% (n = 33) p = 0.93
Creatinin 92.8 + −81.0 88.7 + −68.7 p = 0.57
Renal Insufficiency 8.4% (n = 32) 7.5% (n = 24) p = 0.65
Diabetes melllitus 31.1% n = (118) 23.1% (n = (74) p = 0.019
Hyperlipidemia 59.2% n = (225) 39.1% (n = 125) p < 0.001
Hypertension 58.9% n = (224) 42.2% (n = 135) p < 0.001
Heart failure 2.9% n = (11) 1.3% (n = 4) p = 0.13
Coronary Artery Disease 44.2% n = (168) 34.3% (n = 97) p < 0.001
COPD 15% n = (57) 9.4% (n = 30) p = 0.03
Charlson Score 0.44 ± 0.98 0.31 ± 0.9 p = 0.04
1 year mortality rate 4.6% 1.6% p = 0.03
2 year mortality rate 7.5% 6.2% p = 0.53
5 year mortality rate 19.4% 16.6% p = 0.49